Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab N01 in radiotherapy-refractory thyroid eye disease
ChiCTR2600135818Phase 4Completed
- Sponsor
- Nuclear Industry 416 Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teprotumumab in Graves Orbitopathy (GO), sponsored by Nuclear Industry 416 Hospital. Primary endpoints: Degree of eyelid retraction, Proptosis and 1 more. Started Sep 2025; status: completed.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR2600135818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135818.